BAFF levels are increased in lesional skin and sera in patients with cutaneous T-cell lymphoma

British Journal of Dermatology

Volumn 167, Issue 2, 2012, Pages 359-367

  Ohmatsu, H ^a   Sugaya, M ^a   Miyagaki, T ^a   Suga, H ^a   Fujita, H ^a   Asano, Y ^a   Tada, Y ^a   Kadono, T ^a   Sato, S ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; LACTATE DEHYDROGENASE; MESSENGER RNA; SOLUBLE INTERLEUKIN 2 RECEPTOR;

ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PSORIASIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; B-CELL ACTIVATING FACTOR; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; RNA, MESSENGER; SKIN NEOPLASMS;

EID: 84864401245     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10998.x     Document Type: Article

References (65)

1. Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747-56.
2. Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-3.
3. Shu HB, Hu WH, Johnson H,. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 1999; 65: 680-3.
4. Mukhopadhyay A, Ni J, Zhai Y, et al. Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. J Biol Chem 1999; 274: 15978-81.
5. Nardelli B, Belvedere O, Roschke V, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001; 97: 198-204.
6. Litinskiy MB, Nardelli B, Hilbert DM, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002; 3: 822-9.
7. Craxton A, Magaletti D, Ryan EJ, et al. Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 2003; 101: 4464-71.
8. Krumbholz M, Theil D, Derfuss T, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005; 201: 195-200.
9. Scapini P, Nardelli B, Nadali G, et al. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 2003; 197: 297-302.
10. Ng LG, Sutherland AP, Newton R, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004; 173: 807-17.
11. Mackay F, Leung H,. The role of the BAFF/APRIL system on T cell function. Semin Immunol 2006; 18: 284-9.
12. Chu VT, Enghard P, Riemekasten G, et al. In vitro and in vivo activation induces BAFF and APRIL expression in B cells. J Immunol 2007; 179: 5947-57.
13. Yamada T, Lizhong S, Takahashi N, et al. Poly(I:C) induces BLyS-expression of airway fibroblasts through phosphatidylinositol 3-kinase. Cytokine 2010; 50: 163-9.
14. Reyes LI, León F, González P, et al. Dexamethasone inhibits BAFF expression in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Cytokine 2008; 42: 170-8.
15. Mackay F, Browning JL,. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002; 2: 465-75.
16. Mackay F, Schneider P, Rennert P, et al. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003; 21: 231-64.
17. Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20: 785-98.
18. von Bulow GU, Bram RJ,. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 1997; 278: 138-41.
19. Wang H, Marsters SA, Baker T, et al. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2001; 2: 632-7.
20. Novak AJ, Bram RJ, Kay NE, et al. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002; 100: 2973-9.
21. Kern C, Cornuel JF, Billard C, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004; 103: 679-88.
22. Parameswaran R, Muschen M, Kim YM, et al. A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias. Cancer Res 2010; 70: 4346-56.
23. Novak AJ, Darce JR, Arendt BK, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004; 103: 689-94.
24. Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103: 3148-57.
25. Nishio M, Endo T, Tsukada N, et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005; 106: 1012-20.
26. Mackay F, Tangye SG,. The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers. Curr Opin Pharmacol 2004; 4: 347-54.
27. Cheema GS, Roschke V, Hilbert DM, et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313-19.
28. Zhang J, Roschke V, Baker KP, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6-10.
29. Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48: 3475-86.
30. Matsushita T, Hasegawa M, Yanaba K, et al. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006; 54: 192-201.
31. Yamanishi H, Kumagi T, Yokota T, et al. Clinical significance of B cell-activating factor in autoimmune pancreatitis. Pancreas 2011; 40: 840-5.
32. Groom JR, Fletcher CA, Walters SN, et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 2007; 204: 1959-71.
33. Sarantopoulos S, Stevenson KE, Kim HT, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007; 13: 6107-14.
34. Sarantopoulos S, Stevenson KE, Kim HT, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009; 113: 3865-74.
35. Lavie F, Miceli-Richard C, Quillard J, et al. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J Pathol 2004; 202: 496-502.
36. Seyler TM, Park YW, Takemura S, et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005; 115: 3083-92.
37. Kuwano Y, Fujimoto M, Watanabe R, et al. Serum BAFF and APRIL levels in patients with alopecia areata. J Dermatol Sci 2008; 50: 236-9.
38. Samoud-El Kissi S, Galai Y, Sghiri R, et al. BAFF is elevated in serum of patients with psoriasis: association with disease activity. Br J Dermatol 2008; 159: 765-8.
39. Yamaguchi T, Ohshima K, Tsuchiya T, et al. The comparison of expression of cutaneous lymphocyte-associated antigen (CLA), and Th1- and Th2-associated antigens in mycosis fungoides and cutaneous lesions of adult T-cell leukemia/lymphoma. Eur J Dermatol 2003; 13: 553-9.
40. Kakinuma T, Sugaya M, Nakamura K, et al. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol 2003; 48: 23-30.
41. Notohamiprodjo M, Segerer S, Huss R, et al. CCR10 is expressed in cutaneous T-cell lymphoma. Int J Cancer 2005; 115: 641-7.
42. Vowels BR, Lessin SR, Cassin M, et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 1994; 103: 669-73.
43. Dummer R, Heald PW, Nestle FO, et al. Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood 1996; 88: 1383-9.
44. Saed G, Fivenson DP, Naidu Y, et al. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile. J Invest Dermatol 1994; 103: 29-33.
45. Chong BF, Wilson AJ, Gibson HM, et al. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides. Clin Cancer Res 2008; 14: 646-53.
46. Krejsgaard T, Ralfkiaer U, Clasen-Linde E, et al. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. J Invest Dermatol 2011; 131: 1331-8.
47. Miyagaki T, Sugaya M, Suga H, et al. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma. Clin Cancer Res 2011; 17: 7529-38.
48. Miyagaki T, Sugaya M, Fujita H, et al. Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma. J Invest Dermatol 2010; 130: 2304-11.
49. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-85.
50. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-22.
51. Hanifin JM, Rajka G,. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980; 92: 44-7.
52. Takashima A,. Establishment of fibroblast cultures. In: Current Protocols in Cell Biology. (, Bonifacino JS, Darso M, Harford JB, Lippincott-Schwartz J, Yamada KM, eds.), New Jersey, NJ: John Wiley & Sons, 2001; 2.1.1-2.1.12.
53. Marti RM, Estrach T, Reverter JC, et al. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. Arch Dermatol 1991; 127: 1511-16.
54. Zachariae C, Larsen CS, Kaltoft K, et al. Soluble IL2 receptor serum levels and epidermal cytokines in mycosis fungoides and related disorders. Acta Derm Venereol 1991; 71: 465-70.
55. Wasik MA, Vonderheid EC, Bigler RD, et al. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma clinical and prognostic implications. Arch Dermatol 1996; 132: 42-7.
56. Asano Y, Ihn H, Yamane K, et al. Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest 2004; 113: 253-64.
57. Dobbeling U, Dummer R, Laine E, et al. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood 1998; 92: 252-8.
58. Chen J, Petrus M, Bryant BR, et al. Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia. Blood 2010; 116: 5948-56.
59. Miyagaki T, Sugaya M, Murakami T, et al. CCL11-CCR3 interactions promote survival of anaplastic large cell lymphoma cells via ERK1/2 activation. Cancer Res 2011; 71: 2056-65.
60. Schiemann B, Gommerman JL, Vora K, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293: 2111-14.
61. Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995-9.
62. Avery DT, Kalled SL, Ellyard JI, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003; 112: 286-97.
63. Novak AJ, Grote DM, Stenson M, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004; 104: 2247-53.
64. Matsushita T, Fujimoto M, Echigo T, et al. Elevated serum levels of APRIL, but not BAFF, in patients with atopic dermatitis. Exp Dermatol 2008; 17: 197-202.
65. Hallermann C, Kaune KM, Tiemann M, et al. High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage. Ann Hematol 2007; 86: 509-15.